Flagship explainer
What drives Zevra Therapeutics, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $83.2M | FY2025 |
| |
| Income before tax | $86.7M | FY2025 |
|
| Operating income | −$62.9M | FY2025 |
|
| $106M | FY2025 |
| |
| Ending assets | $285M | FY2025 |
|
| Beginning assets | $178M | FY2024 |
|
| $155M | FY2025 |
| |
| $39.7M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001434647-26-000011